Julian A. Symons - 09 Mar 2026 Form 4 Insider Report for Aligos Therapeutics, Inc. (ALGS)

Role: Executive Vice President, Chief Scientific Officer
Signature: /s/ Lesley Ann Calhoun, as attorney-in fact for Julian A. Symons
Issuer symbol: ALGS
Transactions as of: 09 Mar 2026
Net transactions value: $0
Form type: 4
Filing time: 11 Mar 2026, 16:19:59 UTC
Previous filing: 18 Jul 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Symons Julian A.	Executive Vice President, Chief Scientific Officer	C/O ALIGOS THERAPEUTICS, INC., 1 CORPORATE DRIVE, 2ND FLOOR, SOUTH SAN FRANCISCO	/s/ Lesley Ann Calhoun, as attorney-in fact for Julian A. Symons	11 Mar 2026	0001824727

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ALGS	Stock Option (Right to Buy)	Award		+23,310		$0.000000^*	23,310	09 Mar 2026	Common Stock	23,310	$7.03	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 9, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Remarks:

Executive Vice President, Chief Scientific Officer